The fractional Chief Medical Officer model — a board-certified physician with drug development expertise working part-time across multiple clinical-stage biotechs rather than full-time at one — has grown from a niche arrangement to a genuine market segment since 2020. Our placement data shows a 3x increase in fractional CMO engagements between 2020 and 2024, driven by the convergence of three forces: the proliferation of platform biotechs running multiple IND-enabling programs simultaneously, the acute shortage of physicians with both clinical trial oversight experience and regulatory strategy capability, and the economic reality that a Series A biotech with $30M in funding cannot justify a $650K+ full-time CMO when its lead asset is still in preclinical development.
The fractional CMO market in life sciences is structurally different from fractional executive arrangements in other industries. The regulatory environment — FDA interactions, IND submissions, safety reporting obligations, DSMB oversight — creates accountability requirements that make the "part-time executive" framing more complex than it sounds. This piece examines the compensation structures, time commitments, and decision frameworks that determine whether the fractional model works for a given biotech’s situation.
Compensation structures and retainers
Fractional CMO compensation in the clinical-stage biotech market follows a retainer model rather than an hourly billing structure. Monthly retainers typically range from $15,000 to $30,000, with the variation driven primarily by three factors: the complexity of the therapeutic area (oncology and CNS command premiums over more established modalities), the stage of the lead program (IND-enabling work requires less time than active Phase 2 oversight), and the number of active programs the CMO is expected to oversee.
At the lower end of the range, a fractional CMO working 15 to 20 hours per month on a single preclinical-to-IND program at a platform biotech earns $15,000 to $18,000 monthly. At the upper end, a fractional CMO overseeing two active clinical programs with ongoing FDA interactions, safety monitoring, and investigator management earns $25,000 to $30,000 per month. Equity participation is standard in nearly all fractional CMO arrangements — typically 0.15% to 0.40% of fully diluted shares, vesting over the engagement term with milestone-based acceleration tied to IND acceptance or clinical data readouts.
The annualized gross revenue for an established fractional CMO working with 2 to 3 biotech clients simultaneously ranges from $360,000 to $720,000, before accounting for self-employment costs, malpractice tail coverage, and the administrative overhead of managing multiple engagements. When properly loaded with these costs, the effective compensation is comparable to but generally below a full-time CMO at a funded clinical-stage company, where total compensation packages of $500,000 to $900,000 (base plus bonus plus equity) are standard.
Time commitment and scope
The time commitment for a fractional CMO engagement varies significantly by program phase and regulatory activity. During routine periods between milestones, the engagement may require 10 to 15 hours per month — protocol review, safety data monitoring, CRO oversight calls, and periodic board reporting. During active regulatory periods — pre-IND meetings, IND submissions, end-of-Phase-2 meetings, or safety signal investigations — the time commitment can spike to 30 to 40 hours in a single month.
This variability creates both the opportunity and the risk of the fractional model. The CMO who is managing three concurrent engagements during routine periods is well-utilized and well-compensated. The same CMO facing simultaneous regulatory milestones across multiple clients faces an impossible scheduling conflict that can compromise the quality of work on each program. The most successful fractional CMOs in our network manage this risk by limiting concurrent engagements to companies at different development stages, ensuring that peak-activity periods are unlikely to overlap.
Scope definition is where many fractional CMO arrangements break down. The engagement letter should specify exactly which regulatory activities are included (IND authorship, FDA meeting preparation, safety narrative writing), which are excluded (day-to-day CRO management, site monitoring visits, medical monitoring calls), and what happens when scope expansion is needed. Without these boundaries, a $20,000/month retainer can quickly become a full-time job at a fraction of full-time compensation.
When fractional works vs. full-time hire
The fractional CMO model works well in specific situations and poorly in others. From our placement experience, the model produces good outcomes when three conditions are met simultaneously: the company has a single lead program in early clinical or preclinical development, the CEO or CSO has sufficient scientific depth to manage day-to-day R&D operations without continuous CMO involvement, and the board is aligned on a development timeline that does not require a full-time medical executive for at least 12 to 18 months.
The model breaks down when any of these conditions changes. A company entering Phase 2 with an active comparator trial, multiple clinical sites, and ongoing FDA dialogue needs a full-time CMO whose attention is not divided across other companies’ programs. A company preparing for a partnership or licensing discussion needs a CMO who can be present for diligence meetings on short notice. A company managing a serious adverse event needs a CMO who is immediately available, not one who is in a board meeting for another client.
The transition from fractional to full-time is the most common pattern we see. Approximately 40% of our full-time CMO placements at clinical-stage biotechs involve companies that previously had a fractional CMO and outgrew the model. The decision to transition is typically triggered by one of three events: the lead program entering a registrational study, the company raising a Series B or later round with the expectation of building a permanent medical leadership team, or an FDA interaction that reveals the need for more continuous medical oversight than a fractional arrangement can provide.
Regulatory and compliance implications
The regulatory dimension of fractional CMO arrangements deserves particular attention because the FDA’s expectations do not scale linearly with the CMO’s time commitment. An IND submission lists a medical monitor and clinical responsible party regardless of whether that individual is full-time or fractional. The FDA does not distinguish between a full-time CMO and a fractional one in terms of regulatory accountability. The physician whose name appears on the IND is responsible for safety reporting, protocol amendments, and clinical hold responses on the same timeline whether they work 20 hours per month or 200.
This creates a specific risk for fractional CMOs managing multiple INDs across different sponsors. A safety signal at Company A that requires a Type A meeting with the FDA cannot be deferred because the CMO is working on Company B’s Phase 2 protocol that week. The regulatory clock runs independently of the fractional schedule. CMOs who accept this arrangement must have clear conflict-of-interest protocols, dedicated emergency availability provisions, and explicit agreements about which engagement takes priority in genuine regulatory emergencies.
Companies engaging fractional CMOs should also consider the implications for clinical trial insurance, indemnification, and the CMO’s own malpractice coverage. A fractional CMO operating as an independent contractor may not be covered under the company’s clinical trial liability policy unless explicitly named, and the CMO’s personal malpractice policy may have limitations on coverage for drug development activities conducted outside a traditional employment relationship.
The ideal fractional CMO profile
The physicians who build successful fractional CMO practices in biotech share a specific profile that differs from the ideal full-time CMO candidate. They are typically 15 to 25 years post-residency, with deep expertise in a specific therapeutic area and a track record that includes multiple IND submissions, at least one NDA or BLA, and established relationships with FDA review divisions in their specialty. They have made a deliberate decision to work across multiple programs rather than embed in a single company, often because they value the intellectual variety of working across different modalities and mechanisms of action.
The profile that does not succeed in fractional work: physicians who are between full-time roles and using the fractional model as a bridge while they search for a permanent position. These individuals tend to underinvest in building the client relationships and operational infrastructure that a sustainable fractional practice requires, and they often accept engagements at below-market retainers that undermine their positioning. The fractional CMO market, like any consulting market, rewards specialization, premium pricing, and a genuine commitment to the model.
Final thoughts
The fractional CMO model has genuine utility in the clinical-stage biotech ecosystem, particularly for early-stage companies that need regulatory-grade medical leadership without the cost structure of a full-time executive hire. The 3x growth since 2020 reflects real demand, not a passing trend. However, the model has structural limitations that become binding as programs advance through clinical development, and the regulatory accountability requirements of drug development make fractional medical leadership more complex than fractional executive roles in other industries.
For biotechs evaluating the fractional vs. full-time decision, the question is not whether the fractional model can work in principle — it clearly can — but whether the specific stage of your lead program, the complexity of your regulatory interactions, and the expectations of your board and investors are compatible with a part-time medical executive whose attention is shared across multiple companies. For a related perspective on how senior life sciences careers are structured at the VP and C-suite level, see our Director-to-VP career path analysis.